- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VIRAX BIOLABS GROUP Aktie jetzt für 0€ handeln | |||||
| 10.04. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 31.03. | Virax Biolabs-Tochter erhält ISO-Qualitätszertifizierungen | 1 | Investing.com Deutsch | ||
| 31.03. | Virax BioLabs Group Limited: Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation | 110 | PR Newswire | LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its... ► Artikel lesen | |
| 30.01. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.01. | H.C. Wainwright senkt Kursziel für Virax Biolabs auf 1 US-Dollar | 2 | Investing.com Deutsch | ||
| 12.01. | Virax Biolabs stock price target lowered to $1 at H.C. Wainwright | 1 | Investing.com | ||
| 04.12.25 | Virax Biolabs Unveils $5 Million Private Placement | 4 | RTTNews | ||
| 04.12.25 | Virax Biolabs (VRAX) Stock Cools After Hours Following 75% Rally | 1 | Benzinga.com | ||
| 02.12.25 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.11.25 | Virax BioLabs Group Limited: Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes | 283 | PR Newswire | LONDON, Nov. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection... ► Artikel lesen | |
| 26.08.25 | Virax BioLabs Group Limited: Virax Biolabs Partners with Emory University on ViraxImmune Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September | 291 | PR Newswire | LONDON, Aug. 26, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immune... ► Artikel lesen | |
| 18.07.25 | Virax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency | 308 | PR Newswire | LONDON, July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 87,05 | -3,22 % | BioNTech SE: BioNTech veröffentlicht am 5. Mai 2026 Ergebnisse für das erste Quartal 2026 und informiert über operativen Fortschritt | MAINZ, Deutschland, 21. April 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Dienstag, den 5. Mai 2026, die Ergebnisse für das erste Quartal 2026 veröffentlichen.... ► Artikel lesen | |
| EVOTEC | 5,305 | -1,76 % | Befreiungsschlag für TUI, SAP erhält Zuspruch, auch Evotec werden Chancen nachgesagt, Novo Nordisk glänzt mit Studiendaten doch die Kurse fallen trotzdem | Die ins Stocken gekommenen Verhandlungen im Irankrieg mitsamt neuerliche Eskalationen standen an der Börse zu Wochenbeginn klar im Mittelpunkt. Die Waffenruhe läuft bereits am morgigen Mittwoch aus... ► Artikel lesen | |
| MODERNA | 41,530 | -4,02 % | Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate | Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April... ► Artikel lesen | |
| BIOGEN | 153,74 | -2,26 % | Biogen To Acquire TJ Bio's Rights To Felzartamab In The Greater China Region | WESTON (dpa-AFX) - Biogen Inc. (BIIB) and TJ Biopharma have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to felzartamab in the Greater... ► Artikel lesen | |
| ILLUMINA | 109,46 | +0,29 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 43,075 | +3,47 % | CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? | ||
| VIKING THERAPEUTICS | 27,900 | -0,36 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| ATAIBECKLEY | 3,700 | -6,57 % | Trump weist FDA zur Express-Prüfung von Psychedelika an - Startsignal für Rallye bei Emyria und Atai? | ||
| ASEP MEDICAL | 0,152 | +21,60 % | XFRA JJ80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,820 | +1,61 % | Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business | Ginkgo provides an update on its fourth quarter financial results
BOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today... ► Artikel lesen | |
| TWIST BIOSCIENCE | 49,150 | -5,52 % | Guggenheim reiterates Twist Bioscience stock rating on Amazon tie-up | ||
| OCULAR THERAPEUTIX | 8,100 | 0,00 % | Ocular Therapeutix, Inc.: Ocular Therapeutix to Host Investor Day on June 17, 2026 | ||
| AGIOS | 20,600 | -5,50 % | Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) | ||
| BIOXCEL THERAPEUTICS | 0,922 | +1,32 % | BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions | DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of... ► Artikel lesen | |
| PALISADE BIO | 1,960 | -5,54 % | Palisade Bio, Inc.: Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease | PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat populationPhase 1b data demonstrate endoscopic improvement... ► Artikel lesen |
Das Unternehmen VIRAX BIOLABS GROUP LIMITED kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,140 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIRAX BIOLABS GROUP LIMITED finden Sie auf Wallstreet Online.